1 BTC
=
- USD
Spyre Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Spyre Therapeutics, Inc. Common Stock
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Market Statistics
Trading Metrics
How to Buy SYRE
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy SYRE
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesSpyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share, generating approximately $403 million in gross proceeds. The offering is expected to close on April 16, 2026. Joint book-running managers include Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities, LLC.
Spyre Therapeutics, a clinical-stage biotechnology company focused on inflammatory bowel disease treatments, announced a proposed underwritten public offering of $300 million in common stock, with an additional $45 million option for underwriters. The offering is subject to market conditions and regulatory approval, with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities serving as joint book-running managers.
Spyre Therapeutics, a clinical-stage biotechnology company focused on IBD and immune-mediated diseases, announced a $300 million underwritten public offering of common stock with a potential additional $45 million option for underwriters. The offering is led by Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities as joint book-running managers.
Spyre Therapeutics announced positive Phase 2 SKYLINE trial results for SPY001, an extended half-life anti-α4β7 antibody for moderate-to-severe ulcerative colitis. SPY001 met its primary endpoint with a statistically significant 9.2-point reduction in Robart's Histopathology Index score (p<0.0001) at Week 12, with secondary endpoints showing 40% clinical remission and 51% endoscopic improvement rates. The drug demonstrated a favorable safety profile consistent with its class. Part A enrollment has closed and Part B is now enrolling monotherapy and combination cohorts.
VR Adviser, LLC increased its position in Spyre Therapeutics by 1 million shares (estimated $25.78 million) in Q4, bringing total holdings to 3.68 million shares valued at $120.74 million (5.96% of AUM). Spyre Therapeutics, a preclinical-stage biotech company developing antibody therapies for inflammatory bowel disease, has seen its stock surge 132.1% over the past year. The article cautions that while VR Adviser is specialist biotech fund with deep expertise, Spyre's preclinical status and binary pipeline risk make it unsuitable for most individual investors.